In this single-center, double-blind, randomized trial, we evaluated the effect of intraoperative intravenous administration of Lido and Dex on perioperative serum levels of biomarkers of NETs (MPO and H3Cit) as well as other biomarkers contributing to invasion of cancer in early-stage NSCLC patients. The gene discussed is MPO; the disease is cancer.